(HealthDay)—Peripheral neuropathy (PN) is associated with mortality, even among individuals without diabetes, according to a study published online Dec. 8 in the Annals of Internal Medicine.
Caitlin W. Hicks, M.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues examined the associations between PN and all-cause and cardiovascular mortality in a prospective cohort study involving 7,116 U.S. adults aged 40 years and older with standardized monofilament testing for PN.
The researchers found that the overall prevalence of PN was 13.5 ± 0.5 percent; prevalence was 27.0 ± 1.4 and 11.6 ± 0.5 percent in adults with and without diabetes, respectively. Overall, 2,128 adults died during a median follow-up of 13 years, including 488 who died of cardiovascular causes. Per 1,000 person-years, the incidence rates of all-cause mortality were 57.6, 34.3, 27.1, and 13.0 in adults with diabetes and PN, adults with PN but no diabetes, adults with diabetes but no PN, and adults with no diabetes and no PN, respectively. In adjusted models, in participants with diabetes, PN was significantly associated with all-cause mortality and cardiovascular mortality (hazard ratios [95 percent confidence intervals], 1.49 [1.15 to 1.94] and 1.66 [1.07 to 2.57], respectively). PN was significantly associated with all-cause mortality in those without diabetes (hazard ratio, 1.31; 95 percent confidence interval, 1.15 to 1.50); after adjustment, the association between PN and cardiovascular mortality was no longer statistically significant (hazard ratio, 1.27; 95 percent confidence interval, 0.98 to 1.66).
“These findings suggest that decreased sensation in the foot may be an underrecognized risk factor for death in the general population,” the authors write.
Duration of diabetes history tied to higher short-term mortality risk
Abstract/Full Text (subscription or payment may be required)
Copyright © 2020 HealthDay. All rights reserved.
Peripheral neuropathy linked to mortality in U.S. population (2020, December 11)
retrieved 12 December 2020
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022